Reading the tape
NASDAQ: TGTX
TG Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$5.70B
52w High
$40.99
52w Low
$25.28
P/E
11.41
Volume
1.92M
Outstanding Shares
159.69M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -5.23%Revenue (TTM): 87.32%FCF (TTM): 38.4%P/E: 13th pct
What changed
The stock fell 5.23% over the last year. Revenue grew 87.32% over the trailing twelve months. Operating margin moved from 12.74% to 20.01%. Free cash flow grew 38.4% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 20.01%. A decisive move in revenue — currently up 87.32% — would be the clearest signal to resolve the ambiguity.
Company profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
CEOMichael S. Weiss
SectorHealthcare
IndustryBiotechnology
Employees352
IPO dateMay 3, 2010
Valuation
Forward P/E—
EV/EBITDA33.37
Enterprise value$4.48B
Stock splits
Apr 30, 2012↓ Reverse
Every 225 shares became 4
Jul 14, 2011↓ Reverse
Every 50 shares became 1
Sep 29, 2003↓ Reverse
Every 5 shares became 1
Profitability & growth
Revenue growth78%
Gross margin83.64%▼5.30%vs FY2024
Operating margin20.01%▲57.02%vs FY2024
ROE69.01%▲556.23%vs FY2024
Analyst consensus
RatingBuy
Target price$39.00▲9.23%
11
Buy
1
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est $0.23 · Revenue est $200.33M
View